Tapewire

NYSE · USD

EVMN

Evommune, Inc.

Export transactions ↓
Tapewire entity
5539
SEC CIK
0002044725
Parsed reports
64

Last 12 months

Inside the activity.

7 purchase rows · 9 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202540
Dec 202510
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202602
Jun 202607
Jul 202620
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
July 08, 2026 Filed Jul 10, 2026 23:59 UTC
Carver KyleChief Financial Officer
PurchaseCommon Stock 1,000 $13.26 $13,260.00
Disclosure

SEC source: 0001757072-26-000007 · primarydocument.xml · nonDerivative · entry 1

Carver Kyle · CIK 0001757072 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,335

F1 · kind: The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction.

Read SEC document
July 07, 2026 Filed Jul 9, 2026 00:00 UTC PurchaseCommon Stock 10,000 $13.30 $133,000.00
Disclosure

SEC source: 0001290976-26-000004 · primarydocument.xml · nonDerivative · entry 1

KIRSCH ARTHUR S · CIK 0001290976 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 10,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Read SEC document
June 22, 2026 Filed Jun 25, 2026 00:00 UTC
Patel Jeegar PravinkumarChief Scientific Officer
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 1,488 $0.00 Strike: $3.84 $0.00
Disclosure

SEC source: 0002092017-26-000007 · primarydocument.xml · derivative · entry 3

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,842

Underlying: Common Stock · 1,488 shares

Expires 2033-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

F2 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 22, 2026 Filed Jun 25, 2026 00:00 UTC
Patel Jeegar PravinkumarChief Scientific Officer
SaleCommon Stock 1,488 $22.50 $33,480.00
Disclosure

SEC source: 0002092017-26-000007 · primarydocument.xml · nonDerivative · entry 2

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,403

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

Read SEC document
June 22, 2026 Filed Jun 25, 2026 00:00 UTC
Patel Jeegar PravinkumarChief Scientific Officer
Exercise / conversionCommon Stock 1,488 $3.84 $5,713.92
Disclosure

SEC source: 0002092017-26-000007 · primarydocument.xml · nonDerivative · entry 1

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,891

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

Read SEC document
June 22, 2026 Filed Jun 25, 2026 00:00 UTC
Drew Janice SuzannChief of Dev. Operations
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 16,161 $0.00 Strike: $2.99 $0.00
Disclosure

SEC source: 0002091053-26-000005 · primarydocument.xml · derivative · entry 5

Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,321

Underlying: Common Stock · 16,161 shares

Expires 2034-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026.

F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 22, 2026 Filed Jun 25, 2026 00:00 UTC
Drew Janice SuzannChief of Dev. Operations
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 3,839 $0.00 Strike: $3.84 $0.00
Disclosure

SEC source: 0002091053-26-000005 · primarydocument.xml · derivative · entry 4

Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,795

Underlying: Common Stock · 3,839 shares

Expires 2033-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026.

F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 22, 2026 Filed Jun 25, 2026 00:00 UTC
Drew Janice SuzannChief of Dev. Operations
SaleCommon Stock 20,000 $22.63 $452,600.00
Disclosure

SEC source: 0002091053-26-000005 · primarydocument.xml · nonDerivative · entry 3

Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,794

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
June 22, 2026 Filed Jun 25, 2026 00:00 UTC
Drew Janice SuzannChief of Dev. Operations
Exercise / conversionCommon Stock 16,161 $2.99 $48,321.39
Disclosure

SEC source: 0002091053-26-000005 · primarydocument.xml · nonDerivative · entry 2

Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,794

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026.

Read SEC document
June 22, 2026 Filed Jun 25, 2026 00:00 UTC
Drew Janice SuzannChief of Dev. Operations
Exercise / conversionCommon Stock 3,839 $3.84 $14,741.76
Disclosure

SEC source: 0002091053-26-000005 · primarydocument.xml · nonDerivative · entry 1

Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 23:59 UTC
Pena Luis C.Director · President & CEO
SaleCommon Stock 7,438 $22.71 $168,916.98
Disclosure

SEC source: 0001620548-26-000007 · primarydocument.xml · nonDerivative · entry 1

Pena Luis C. · CIK 0001620548 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 630,458

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $22.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
June 02, 2026 Filed Jun 4, 2026 00:04 UTC GrantStock Option (Right to buy) · Derivative 15,673 $0.00 Strike: $19.82 $0.00
Disclosure

SEC source: 0001216994-26-000003 · primarydocument.xml · derivative · entry 1

MCGRAW BENJAMIN F III · CIK 0001216994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,673

Underlying: Common Stock · 15,673 shares

Expires 2036-06-01

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 02, 2026 Filed Jun 4, 2026 00:03 UTC GrantStock Option (Right to buy) · Derivative 15,673 $0.00 Strike: $19.82 $0.00
Disclosure

SEC source: 0001290976-26-000002 · primarydocument.xml · derivative · entry 1

KIRSCH ARTHUR S · CIK 0001290976 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,673

Underlying: Common Stock · 15,673 shares

Expires 2036-06-01

F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 02, 2026 Filed Jun 4, 2026 00:03 UTC GrantStock Option (Right to buy) · Derivative 15,673 $0.00 Strike: $19.82 $0.00
Disclosure

SEC source: 0001347383-26-000003 · primarydocument.xml · derivative · entry 3

Cohen David E · CIK 0001347383 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,673

Underlying: Common Stock · 15,673 shares

Expires 2036-06-01

F4 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 02, 2026 Filed Jun 4, 2026 00:03 UTC SaleCommon Stock 600 $21.38 $12,828.00
Disclosure

SEC source: 0001347383-26-000003 · primarydocument.xml · nonDerivative · entry 2

Cohen David E · CIK 0001347383 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,609

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
June 02, 2026 Filed Jun 4, 2026 00:03 UTC SaleCommon Stock 5,456 $20.21 $110,265.76
Disclosure

SEC source: 0001347383-26-000003 · primarydocument.xml · nonDerivative · entry 1

Cohen David E · CIK 0001347383 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,209

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
June 01, 2026 Filed Jun 4, 2026 00:02 UTC
Patel Jeegar PravinkumarChief Scientific Officer
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 13,512 $0.00 Strike: $3.84 $0.00
Disclosure

SEC source: 0002092017-26-000005 · primarydocument.xml · derivative · entry 3

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,330

Underlying: Common Stock · 13,512 shares

Expires 2033-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 01, 2026 Filed Jun 4, 2026 00:02 UTC
Patel Jeegar PravinkumarChief Scientific Officer
SaleCommon Stock 16,687 $22.74 $379,462.38
Disclosure

SEC source: 0002092017-26-000005 · primarydocument.xml · nonDerivative · entry 2

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,403

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
June 01, 2026 Filed Jun 4, 2026 00:02 UTC
Patel Jeegar PravinkumarChief Scientific Officer
Exercise / conversionCommon Stock 13,512 $3.84 $51,886.08
Disclosure

SEC source: 0002092017-26-000005 · primarydocument.xml · nonDerivative · entry 1

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

Read SEC document
June 01, 2026 Filed Jun 4, 2026 00:02 UTC
Pena Luis C.Director · President & CEO
SaleCommon Stock 16,787 $22.74 $381,736.38
Disclosure

SEC source: 0001620548-26-000005 · primarydocument.xml · nonDerivative · entry 1

Pena Luis C. · CIK 0001620548 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 637,896

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
May 28, 2026 Filed Jun 2, 2026 00:00 UTC
Moss Gregory S.Chief Business & Legal Officer
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 14,223 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001742496-26-000005 · primarydocument.xml · derivative · entry 4

Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,845

Underlying: Common Stock · 14,223 shares

Expires 2034-03-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.

F4 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
May 28, 2026 Filed Jun 2, 2026 00:00 UTC
Moss Gregory S.Chief Business & Legal Officer
SaleCommon Stock 14,223 $22.83 $324,711.09
Disclosure

SEC source: 0001742496-26-000005 · primarydocument.xml · nonDerivative · entry 2

Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,835

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
May 28, 2026 Filed Jun 2, 2026 00:00 UTC
Moss Gregory S.Chief Business & Legal Officer
Exercise / conversionCommon Stock 14,223 $1.71 $24,321.33
Disclosure

SEC source: 0001742496-26-000005 · primarydocument.xml · nonDerivative · entry 1

Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,058

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 23:59 UTC
Carver KyleChief Financial Officer
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $2.99 $0.00
Disclosure

SEC source: 0001757072-26-000005 · primarydocument.xml · derivative · entry 3

Carver Kyle · CIK 0001757072 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,731

Underlying: Common Stock · 15,000 shares

Expires 2034-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.

F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 23:59 UTC
Carver KyleChief Financial Officer
SaleCommon Stock 18,175 $22.84 $415,117.00
Disclosure

SEC source: 0001757072-26-000005 · primarydocument.xml · nonDerivative · entry 2

Carver Kyle · CIK 0001757072 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,335

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 23:59 UTC
Carver KyleChief Financial Officer
Exercise / conversionCommon Stock 15,000 $2.99 $44,850.00
Disclosure

SEC source: 0001757072-26-000005 · primarydocument.xml · nonDerivative · entry 1

Carver Kyle · CIK 0001757072 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 21:24 UTC
Patel Jeegar PravinkumarChief Scientific Officer
GrantEmployee Stock Option (Right to Buy) · Derivative 69,315 $0.00 Strike: $26.77 $0.00
Disclosure

SEC source: 0002092017-26-000003 · primarydocument.xml · derivative · entry 1

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,315

Underlying: Common Stock · 69,315 shares

Expires 2036-04-15

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 21:24 UTC
Drew Janice SuzannChief of Dev. Operations
GrantEmployee Stock Option (Right to Buy) · Derivative 73,892 $0.00 Strike: $26.77 $0.00
Disclosure

SEC source: 0002091053-26-000003 · primarydocument.xml · derivative · entry 1

Drew Janice Suzann · CIK 0002091053 · Chief of Dev. Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,892

Underlying: Common Stock · 73,892 shares

Expires 2036-04-15

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 21:23 UTC
Bauer EugeneDirector · Chief Medical Officer
GrantEmployee Stock Option (Right to Buy) · Derivative 51,117 $0.00 Strike: $26.77 $0.00
Disclosure

SEC source: 0001678620-26-000003 · primarydocument.xml · derivative · entry 1

Bauer Eugene · CIK 0001678620 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,117

Underlying: Common Stock · 51,117 shares

Expires 2036-04-15

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 21:23 UTC
Carver KyleChief Financial Officer
GrantEmployee Stock Option (Right to Buy) · Derivative 98,946 $0.00 Strike: $26.77 $0.00
Disclosure

SEC source: 0001757072-26-000003 · primarydocument.xml · derivative · entry 1

Carver Kyle · CIK 0001757072 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,946

Underlying: Common Stock · 98,946 shares

Expires 2036-04-15

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 21:23 UTC
Moss Gregory S.Chief Business & Legal Officer
GrantEmployee Stock Option (Right to Buy) · Derivative 115,279 $0.00 Strike: $26.77 $0.00
Disclosure

SEC source: 0001742496-26-000003 · primarydocument.xml · derivative · entry 1

Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,279

Underlying: Common Stock · 115,279 shares

Expires 2036-04-15

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
April 16, 2026 Filed Apr 17, 2026 21:23 UTC
Pena Luis C.Director · President & CEO
GrantEmployee Stock Option (Right to Buy) · Derivative 291,420 $0.00 Strike: $26.77 $0.00
Disclosure

SEC source: 0001620548-26-000003 · primarydocument.xml · derivative · entry 1

Pena Luis C. · CIK 0001620548 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 291,420

Underlying: Common Stock · 291,420 shares

Expires 2036-04-15

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
February 17, 2026 Filed Feb 18, 2026 00:28 UTC GrantCommon Stock 35,868 $27.88 $999,999.84
Disclosure

SEC source: 0001231919-26-000164 · form4-02182026_120251.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,710,293

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F2 · ownership.nature: Held directly by the Fund.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 02:19 UTC GrantCommon Stock 358,680 $27.88 $9,999,998.40
Disclosure

SEC source: 0002094941-26-000002 · form4-02192026_020236.xml · nonDerivative · entry 1

Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By LSP 7 Cooperatief U.A.

Disclosed balance after: 5,288,313

F1 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:30 UTC
LSP 7 Cooperative UADirector · 10% owner
GrantCommon Stock 358,680 $27.88 $9,999,998.40
Disclosure

SEC source: 0001193125-26-059500 · ownership.xml · nonDerivative · entry 1

LSP 7 Cooperative UA · CIK 0001876264 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 5,288,313

F1 · ownership.nature: Securities held of record by LSP 7 Cooperatief UA ("LSP 7"). LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP 7 Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to share beneficial ownership of the shares of Common Stock held by LSP 7. Each of Mr. Kleijwegt, Mr. Kuijten and Mr. Rothe disclaims beneficial ownership of such shares.

Read SEC document
December 19, 2025 Filed Dec 22, 2025 12:07 UTC
Hopfner Robert LorneDirector · 10% owner
PurchaseCommon Stock 1,000 $17.35 $17,350.00
Disclosure

SEC source: 0001012975-25-000937 · form4.xml · nonDerivative · entry 1

Hopfner Robert Lorne · CIK 0001551966 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 4,026

F1 · ownership.nature: The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:22 UTC
Patel Jeegar PravinkumarChief Scientific Officer
Tax withholdingCommon Stock 7,513 $17.84 $134,031.92
Disclosure

SEC source: 0002092017-25-000009 · primarydocument.xml · nonDerivative · entry 1

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,578

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:21 UTC
Drew Janice SuzannEVP, Operations
Tax withholdingCommon Stock 5,074 $17.84 $90,520.16
Disclosure

SEC source: 0002091053-25-000009 · primarydocument.xml · nonDerivative · entry 1

Drew Janice Suzann · CIK 0002091053 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,794

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:23 UTC
Pena Luis C.Director · President & CEO
Tax withholdingCommon Stock 28,138 $17.84 $501,981.92
Disclosure

SEC source: 0001620548-25-000011 · primarydocument.xml · nonDerivative · entry 1

Pena Luis C. · CIK 0001620548 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 654,683

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:20 UTC
Carver KyleChief Financial Officer
Tax withholdingCommon Stock 13,290 $17.84 $237,093.60
Disclosure

SEC source: 0001757072-25-000010 · primarydocument.xml · nonDerivative · entry 1

Carver Kyle · CIK 0001757072 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,510

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:22 UTC
Moss Gregory S.Chief Business & Legal Officer
Tax withholdingCommon Stock 13,624 $17.84 $243,052.16
Disclosure

SEC source: 0001742496-25-000012 · primarydocument.xml · nonDerivative · entry 1

Moss Gregory S. · CIK 0001742496 · Chief Business & Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,835

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
December 09, 2025 Filed Dec 11, 2025 21:18 UTC
Bauer EugeneDirector · Chief Medical Officer
Tax withholdingCommon Stock 1,478 $17.84 $26,367.52
Disclosure

SEC source: 0001678620-25-000011 · primarydocument.xml · nonDerivative · entry 1

Bauer Eugene · CIK 0001678620 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 270,818

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Read SEC document
December 08, 2025 Filed Dec 19, 2025 21:06 UTC
Bauer EugeneDirector · Chief Medical Officer
GrantEmployee Stock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $18.44 $0.00
Disclosure

SEC source: 0001678620-25-000013 · primarydocument.xml · derivative · entry 1

Bauer Eugene · CIK 0001678620 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2035-12-08

F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on December 8, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:21 UTC
Patel Jeegar PravinkumarChief Scientific Officer
ConversionSeries B Preferred Stock · Derivative 25,000 Not disclosed Not disclosed
Disclosure

SEC source: 0002092017-25-000007 · form4-11122025_091148.xml · derivative · entry 2

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,175 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:21 UTC
Patel Jeegar PravinkumarChief Scientific Officer
ConversionCommon Stock 3,175 Not disclosed Not disclosed
Disclosure

SEC source: 0002092017-25-000007 · form4-11122025_091148.xml · nonDerivative · entry 1

Patel Jeegar Pravinkumar · CIK 0002092017 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,091

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:18 UTC
Drew Janice SuzannEVP, Operations
ConversionSeries B Preferred Stock · Derivative 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0002091053-25-000007 · form4-11122025_091133.xml · derivative · entry 2

Drew Janice Suzann · CIK 0002091053 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,587 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:18 UTC
Drew Janice SuzannEVP, Operations
ConversionCommon Stock 1,587 Not disclosed Not disclosed
Disclosure

SEC source: 0002091053-25-000007 · form4-11122025_091133.xml · nonDerivative · entry 1

Drew Janice Suzann · CIK 0002091053 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:24 UTC ConversionSeries C Preferred Stock · Derivative 6,585,011 Not disclosed Not disclosed
Disclosure

SEC source: 0002094941-25-000004 · form4-11122025_091104.xml · derivative · entry 5

Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By LSP 7 Cooperatief U.A.

Disclosed balance after: 0

Underlying: Common Stock · 773,069 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F3 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F3 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F3 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.

F4 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:24 UTC ConversionSeries B Preferred Stock · Derivative 5,090,000 Not disclosed Not disclosed
Disclosure

SEC source: 0002094941-25-000004 · form4-11122025_091104.xml · derivative · entry 4

Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By LSP 7 Cooperatief U.A.

Disclosed balance after: 0

Underlying: Common Stock · 646,587 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F2 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F2 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F2 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.

F4 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.

Read SEC document
November 07, 2025 Filed Nov 12, 2025 21:24 UTC ConversionSeries A Preferred Stock · Derivative 15,493,466 Not disclosed Not disclosed
Disclosure

SEC source: 0002094941-25-000004 · form4-11122025_091104.xml · derivative · entry 3

Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By LSP 7 Cooperatief U.A.

Disclosed balance after: 0

Underlying: Common Stock · 1,947,477 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F1 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date.

F4 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.